Related Experiment Videos
Ketorolac prophylaxis against heterotopic ossification after hip replacement
1Department of Orthopaedic Surgery, University of Washington, Seattle 98144, USA.
Clinical Orthopaedics and Related Research
|May 1, 1995
Summary
Ketorolac effectively prevents heterotopic bone formation after total hip replacement surgery. This non-steroidal anti-inflammatory drug significantly reduced bone growth, with no observed complications in patients.
Area of Science:
- Orthopedic Surgery
- Pharmacology
Background:
- Heterotopic bone formation (HOF) is a common complication following total hip replacement (THR).
- Preventing HOF is crucial for patient recovery and joint function.
Purpose of the Study:
- To evaluate the efficacy of ketorolac in preventing heterotopic bone formation after primary total hip arthroplasty.
- To assess the safety and compliance of ketorolac prophylaxis.
Main Methods:
- Prospective, randomized, double-blind clinical study.
- 303 patients undergoing primary THR for osteoarthritis received either ketorolac or no prophylaxis.
- Ketorolac group received 60 mg intraoperatively and 30 mg every 8 hours for 5 postoperative doses.
Main Results:
- Significantly less heterotopic bone formation in the ketorolac group compared to controls.
- No severe heterotopic bone formation occurred in any ketorolac-treated patients.
- No ketorolac-related complications were observed.
Conclusions:
- Ketorolac is effective for preventing heterotopic bone formation after total hip replacement.
- Ensured compliance due to in-hospital administration.
- Convenient prophylactic option, though not necessarily superior to other treatments.